{"acquisitions":[],"changes":[],"country":"GB","description":"Verdiva Bio is a UK biotech developing once-weekly oral GLP-1 analogs and other obesity and cardiometabolic therapies. Patients with obesity and cardiometabolic disease are the eventual customer base. Lead program VRB-101 is an oral ecnoglutide in Phase 2 clinical development.","domain":"verdivabio.com","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":51.515066,"lng":-0.142502,"location":"Guildford, UK","multiples":[],"name":"Verdiva Bio","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":411000000,"connectionsAmong":[],"currency":"USD","date":"2025-01-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"verdivabio-com-2025-01-01-series-a","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-04-29","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"verdivabio-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-04-29","status":"attributed","url":null},{"fact":"existence","publisher":"verdivabio.com","retrievedAt":"2026-04-29","status":"self-reported","url":"https://verdivabio.com"},{"fact":"description","publisher":"verdivabio.com","retrievedAt":"2026-04-29","status":"self-reported","url":"https://verdivabio.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Nginx","Mailcheck 1.1.2","Yoast SEO 27.6","reCAPTCHA","Google Analytics","Google Tag Manager","Slick","jQuery Migrate 3.4.1","jsDelivr","Plesk","punycode 1.0.0","DoubleClick Floodlight"],"totalRaisedUsd":411000000,"traction":[],"updatedAt":"2026-04-29","valuations":[]}